fashion -WSS

fashion

author：Wikipedia 2025-10-03 00:38:26 - browse：8

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： NIH study of ME/CFS points to clear biological hallmarks

Wikipedia

WSS

NIH study of ME/CFS points to clear biological hallmarks

Antivenom research: Lessons from HIV applied in search for universal antidote

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Alabama hospital puts IVF treatments on hold

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

As AI in medicine takes off, can 'human in the loop' prevent harm?

Sports medicine is finally prioritizing gender equality

President Biden's budget: Here's what you might have missed

Drug repurposing or repositioning? The language matters

As AI in medicine takes off, can 'human in the loop' prevent harm?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Alabama hospital puts IVF treatments on hold

Sports medicine is finally prioritizing gender equality

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

focus

Why palliative psychiatry is worth discussing

Medicare coverage of Wegovy, once blocked, now looks possible

In utero gene editing: an explainer

The Harvard botanist who searched for psychedelics in the Amazon

PBM reform efforts get punted in Congress

RaDonda Vaught links Vanderbilt hospital issues to patient death

explore

Wikipedia

hotspot

hotspot